H Lundbeck A/S
CSE:HLUN A
Gross Margin
H Lundbeck A/S
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| DK |
|
H Lundbeck A/S
CSE:HLUN A
|
29.8B DKK |
83%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.9B USD |
82%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.3B USD |
68%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
84%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.2B CHF |
74%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
185.9B CHF |
76%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.1B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
198.9B USD |
78%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
136.3B USD |
75%
|
H Lundbeck A/S
Glance View
Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on H Lundbeck A/S's most recent financial statements, the company has Gross Margin of 82.7%.
You don't have any saved screeners yet